MajorAntiplatelet agents – P2Y12 receptor inhibitors×Direct thrombin inhibitor
Updated · Methodology
Mechanism
Dabigatran is a direct, competitive and reversible inhibitor of thrombin, the key clotting enzyme (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). The active metabolite of clopidogrel irreversibly blocks the platelet P2Y12 receptor. Platelets exposed to it stay affected for the rest of their lifespan, about 7–10 days (clopidogrel SmPC, EMA). In the RE-LY study in atrial fibrillation, concomitant acetylsalicylic acid or clopidogrel roughly doubled the rate of major bleeding with both dabigatran and warfarin (dabigatran SmPC, EMA). In healthy volunteers, clopidogrel given with dabigatran did not prolong bleeding time beyond clopidogrel alone. After a clopidogrel loading dose of 300 mg or 600 mg, however, dabigatran AUC and Cmax rose by about 30–40% (EMA).
Symptoms
The risk of bleeding rises. It may be overt or hidden, occur in any tissue or organ and may be fatal (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). With long-term dabigatran, mucosal bleeding, such as gastrointestinal and genitourinary bleeding, was seen more often than with vitamin K antagonists (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or unexplained shock (EMA). In people taking clopidogrel, bleeding may last longer than usual (clopidogrel SmPC, EMA).
Management
The combination is not contraindicated. The clopidogrel summary of product characteristics (SmPC), however, does not recommend combining clopidogrel with oral anticoagulants, dabigatran included, because bleeding may become more severe (clopidogrel SmPC, European Medicines Agency, EMA). Antiplatelets significantly increase the risk of major bleeding, so weigh benefit and risk carefully and give dabigatran only if the benefit outweighs the bleeding risk (dabigatran SmPC, EMA). The dabigatran SmPC names one exception: patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention with stenting can be treated with dabigatran plus antiplatelets once haemostasis is achieved (EMA). In atrial fibrillation patients at higher bleeding risk, choose a daily dabigatran dose of 300 mg or 220 mg after an individual assessment of thromboembolic and bleeding risk (EMA). While the drugs are combined, watch closely for signs of bleeding or anaemia (EMA) and for any sign of bleeding, including hidden bleeding, especially in the first weeks of clopidogrel treatment and after surgery. If symptoms suggest bleeding, promptly decide whether a full blood count is needed (clopidogrel SmPC, EMA). If haemoglobin, haematocrit or blood pressure falls without explanation, look for a bleeding site. Stop dabigatran if clinically relevant bleeding occurs (dabigatran SmPC, EMA). Before elective surgery, if an antiplatelet effect is not needed, stop clopidogrel 7 days in advance (clopidogrel SmPC, EMA). The time to stop dabigatran, from 24 hours to 4 days, depends on creatinine clearance and the bleeding risk of the procedure (dabigatran SmPC, EMA). The 2021 European Heart Rhythm Association practical guide (EHRA 2021) lists concomitant antiplatelets among bleeding risk factors that require caution, and says that an anticoagulant combined with dual antiplatelet therapy requires active measures to prevent bleeding.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica Plavix 75 mg comprimidos recubiertos con película (clopidogrel) (2022)– AEMPS CIMA, ficha técnica Plavix 75 mg, nº registro 98069001 (EU/1/98/069), texto EMA, revisión diciembre 2022, secciones 4.2, 4.4 y 4.5
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 (tabla 4), 4.5 (tabla 8) y 4.8